A novel germline mutation in Peroxisome Proliferator-Activated Receptor γ gene associated with large intestine polyp formation and dyslipidemia

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 6, 2010, Pages 572-581

  Capaccio, D ^a,c   Ciccodicola, A ^b   Sabatino, L ^a,c   Casamassimi, A ^b   Pancione, M ^a   Fucci, A ^a   Febbraro, A ^d   Merlino, A ^c   Graziano, G ^a   Colantuoni, V ^a,c  

^a UNIVERSITY OF SANNIO   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Colorectal cancer; Dyslipidemia; Loss of function mutation; Peroxisome Proliferator Activated Receptor

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER LOCALIZATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLON CARCINOGENESIS; COLON POLYP; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GERM LINE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; LIGAND BINDING; LIPID METABOLISM; LIVER METASTASIS; LOSS OF FUNCTION MUTATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANIMALS; BASE SEQUENCE; BINDING SITES; CERCOPITHECUS AETHIOPS; COLONIC NEOPLASMS; COS CELLS; DNA PRIMERS; DYSLIPIDEMIAS; FEMALE; GERM-LINE MUTATION; HUMANS; INTESTINAL POLYPS; LOSS OF HETEROZYGOSITY; MALE; MICE; MIDDLE AGED; MODELS, MOLECULAR; NIH 3T3 CELLS; PEDIGREE; PPAR GAMMA; RECOMBINANT PROTEINS; TRANSFECTION; YOUNG ADULT;

EID: 77952240564     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.01.012     Document Type: Article

References (37)

1. Francis G.A., Fayard E., Picard F., Auwerx J. Nuclear receptors and the control of metabolism. Ann. Rev. Physiol. 2003, 65:261-311.
2. Spiegelman B.M. PPARγ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47:507-514.
3. Feige J.N., Gelman L., Michalik L., Desvergne B., Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res. 2006, 45:120-159.
4. Willson T.M., Lambert M.H., Kliewer S.A. Peroxisome proliferator-activated receptor γ and metabolic disease. Annu. Rev. Biochem. 2001, 70:341-367.
5. Knouff C., Auwerx J. Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology. Endocr. Rev. 2004, 25:899-918.
6. Sarraf P., Mueller E., Smith W.M., Wright H.M., Kum J.B., Aaltonen L.A., de la Chapelle A., Spiegelman B.M., Eng C. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol Cell 1999, 3:799-804.
7. Ristow M., Muller-Wieland D., Pfeiffer A., Krone W., Kahn C.R. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med. 1998, 339:953-959.
8. Michalik L., Desvergne B., Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat. Rev. Cancer 2004, 4:61-70.
9. Grommes C., Landreth G., Heneka M.T. Antineoplastic effects of peroxisome proliferator activated receptor γ agonists. Lancet Oncol. 2004, 7:419-429.
10. Sabatino L., Casamassimi A., Peluso G., Barone M.V., Capaccio D., Migliore C., Monelli P., Pedicini A., Febbraro A., Ciccodicola A., Colantuoni V. A novel peroxisome proliferator-activated receptor γ isoform with dominant negative activity generated by alternative splicing. J. Biol. Chem. 2005, 280:26517-26525.
11. Barroso I., Gurnell M., Crowley V.E., Agostini M., Schwabe J.W., Soos M.A., Maslen G.L., Williams T.D., Lewis H., Schafer A.J., Chatterjee V.K., O'Rahilly S. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402:880-883.
12. Savage D.B., Tan G.D., Acerini C.L., Jebb S.A., Agostini M., Gurnell M., Williams R.L., Umpleby A.M., Thomas E.L., Bell J.D., Dixon A.K., Dunne F., Boiani R., Cinti S., Vidal-Puig A., Karpe F., Chatterjee V.K., O'Rahilly S. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor γ. Diabetes 2003, 52:910-917.
13. Peverali F.A., Ramqvist T., Saffrich R., Pepperkok R., Barone M.V., Philipson L. Regulation of G1 progression by E2A and Id helix-loop-helix proteins. EMBO J. 1994, 13:4291-4301.
14. Barone M.V., Courtneidge S.A. Myc but not Fos rescue of PDGF signaling block caused by kinase-inactive Src. Nature 1995, 378:509-512.
15. Pancione M., Forte N., Sabatino L., Tomaselli E., Parente D., Febbraro A., Colantuoni V. Reduced γ-catenin and peroxisome proliferator-activated receptor γ expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Hum. Pathol. 2009, 40:714-725.
16. Yeh J.J., Marsh D.J., Zedenius J., Dwight T., Delbridge L., Robinson B.G., Eng C. Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. Genes Chromosomes Cancer 1999, 26:322-328.
17. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
18. Gupta R.A., Sarraf P., Mueller E., Brockman J.A., Prusakiewicz J.J., Eng C., Willson T.M., DuBois R.N. Peroxisome proliferator-activated receptor γ mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms. J. Biol. Chem. 2003, 278:22669-22677.
19. Girnun G.D., Smith W.M., Drori S., Sarraf P., Mueller E., Eng C., Nambiar P., Rosenberg D.W., Bronson R.T., Edelmann W., Kucherlapati R., Gonzalez F.J., Spiegelman B.M. APC-dependent suppression of colon carcinogenesis by PPARγ. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13771-13776.
20. Teresi R.E., Shaiu C.W., Chen C.S., Chatterjee V.K., Waite K.A., Eng C. Increased PTEN expression due to transcriptional activation of PPARγ by lovastatin and rosiglitazone. Int. J. Cancer 2006, 118:2390-2398.
21. Annicotte J.S., Iankova I., Miard S., Fritz V., Sarruf D., Abella A., Berthe M.L., Noël D., Pillon A., Iborra F., et al. Peroxisome proliferator-activated receptor γ regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol. Cell. Biol. 2006, 26:7561-7574.
22. Wang D., Dubois R.N. Peroxisome proliferator-activated receptors and progression of colorectal cancer. PPAR Res 2008, 931074.
23. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPARγ. Nature 2005, 437:759-763.
24. Iatropoulos M.J., Williams G.M. Proliferation markers. Exp. Toxicol. Pathol. 1996, 48:175-181.
25. Platt A.M., Mowat A.M. Mucosal macrophages and the regulation of immune responses in the intestine. Immunol. Lett. 2008, 119:22-31.
26. Mori M., Shimono R., Adachi Y., Matsuda H., Kuwano H., Sugimachi K., Ikeda M., Saku M. Transitional mucosa in human colorectal lesions. Dis. Colon Rectum 1990, 33:498-501.
27. Gampe R.T., Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K., Milburn M.V., Kliever S.A., Willson T.M., Xu E.H. Asymmetry in the PPARγ /RXRγ crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 2000, 5:545-555.
28. Uppenberg J., Svensson C., Jaki M., Bertilsson G., Jendeberg L., Berkenstam A. Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ. J. Biol. Chem. 1998, 273:31108-31112.
29. Petersen M.T., Jonson P.H., Petersen S.B. Amino acid neighbours and detailed conformational analysis of cysteines in proteins. Protein Eng. 1999, 12:535-548.
30. Kraulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 1991, 24:946-950.
31. Rogler G. Significance of anti-inflammatory effects of PPARγ agonists?. Gut 2006, 55:1067-1069.
32. Alberici P., Gaspar C., Franken P., Gorski M.M., de Vries I., Scott R.J., Ristimäki A., Aaltonen L.A., Fodde R. Smad4 haploinsufficiency: a matter of dosage. Pathogenetics 2008, 1:2-12.
33. Eng C., Schneider K., Fraumeni J.F., Li F.P. Third international workshop on collaborative interdisciplinary studies of p53 and other predisposing genes in Li-Fraumeni syndrome. Cancer Epidemiol. Biomarkers Prev. 1997, 6:379-383.
34. Russell-Swetek A., West A.N., Mintern J.E., Jenkins J., Rodriguez-Galindo C., Ribeiro R., Zambetti G.P. Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma. J. Med. Genet. 2008, 45:603-606.
35. Ikezoe T., Miller C.W., Kawano S., Heaney A., Williamson E.A., Hisatake J., Green E., Hofmann W., Taguchi H., Koeffler H.P. Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Cancer Res. 2001, 61:5307-5310.
36. Tsai Y.S., Kim H.J., Takahashi N., Kim H.S., Hagaman J.R., Kim J.K., Maeda N. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ. J. Clin. Invest 2004, 114:163-175.
37. Meredith D., Panchatcharam M., Miriyala S., Tsai Y.S., Morris A.J., Maeda N., Stouffer G.A., Smyth S.S. Dominant-negative loss of PPARγ function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler. Thromb. Vasc. Biol. 2009, 29:465-471.